During the corresponding time, Lenz Therapeutics Inc recorded a revenue increase by 9.72 % year on year, sequentially revenue grew by 188.58 %. While revenue at the Lenz Therapeutics Inc 's corporate clients
Lenz Therapeutics Inc's Comment on Sales, Marketing and Customers
The company develops treatments for presbyopia, a condition affecting an estimated 1.8 billion people globally, including 128 million in the U.S., characterized by age-related loss of near vision. Its product, VIZZ (aceclidine ophthalmic solution) 1.44%, is a once-daily eye drop intended to restore clear near vision for up to 10 hours. Presbyopes often self-diagnose and manage the condition with over-the-counter reading glasses or seek professional care involving prescription glasses or contact lenses. The presbyopia treatment market includes pharmaceutical products such as Vuity by AbbVie, Qlosi by Orasis, a generic version of Vuity by Amneal Therapeutics, and Yuvezzi, approved by the FDA and potentially launched by Tenpoint Therapeutics. VIZZ became broadly available in retail pharmacies in November 2025 and through an e-pharmacy partner in October 2025.
In a significant development within the pharmaceutical sector, LENZ Therapeutics has announced an exclusive licensing and commercialization agreement with Lotus Pharmaceutical for its novel product, LNZ100, in the Republic of Korea and Southeast Asia. This agreement not only underscores the growing interest in innovative therapeutic solutions but also highlights the strategic partnerships essential for enhancing market penetration and scalability in the biopharmaceutical landscape.Under the terms of this exclusive agreement, LENZ Therapeutics stands to receive up to $125 million in upfront and milestone payments. This financial arrangement reflects both parties confidence in LNZ100 s potential and establish...
In a significant milestone for the field of ophthalmology, SAN DIEGO-based LENZ Therapeutics, Inc. (Nasdaq: LENZ), has announced a major development that promises to bring tr...
Lenz Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company develops treatments for presbyopia, a condition affecting an estimated 1.8 billion people globally, including 128 million in the U.S., characterized by age-related loss of near vision. Its product, VIZZ (aceclidine ophthalmic solution) 1.44%, is a once-daily eye drop intended to restore clear near vision for up to 10 hours. Presbyopes often self-diagnose and manage the condition with over-the-counter reading glasses or seek professional care involving prescription glasses or contact lenses. The presbyopia treatment market includes pharmaceutical products such as Vuity by AbbVie, Qlosi by Orasis, a generic version of Vuity by Amneal Therapeutics, and Yuvezzi, approved by the FDA and potentially launched by Tenpoint Therapeutics. VIZZ became broadly available in retail pharmacies in November 2025 and through an e-pharmacy partner in October 2025.
Sources:
Lenz Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lenz Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lenz Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
14.58 %